Dr. Lal PathLabs Ltd.Q1 FY27 Results & Financial Update
Dr. Lal PathLabs Ltd.: Q1 FY27 consolidated results and company financials – revenue ₹797.70 Cr, PAT ₹170.50 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Dr. Lal PathLabs price & chart
Market price₹1,859.90
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Dr. Lal PathLabs Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Dr. Lal PathLabs recorded a consolidated operational revenue of INR 797.7 crore for the quarter ended June 30, 2026, accompanied by a total income of INR 829.6 crore.
According to company earnings presentations and press releases, consolidated revenue expanded by 19.1% year-on-year, driven by robust volume growth that management noted as the highest quarterly revenue growth rate achieved in the last four years.
Profit after tax (PAT) for the quarter reached INR 170.5 crore, reflecting strong underlying operational profitability and disciplined cost management across collection networks and employee expenses.
Operational momentum was underpinned by strong patient and sample volumes, with sample volumes growing by 10.7% year-on-year to 25.9 million and patient volumes increasing by 8.2% year-on-year to 8.2 million during Q1 FY27.
The company's board approved an interim dividend of INR 5 per equity share (50% on a face value of INR 10 each) for FY 2026-27, with the record date set for July 30, 2026.
Strategic expansion efforts continued during the quarter with the incorporation of a wholly-owned subsidiary in Dubai, Dr Lal Pathlabs FZCO, and subsequent board approval by the subsidiary to acquire an 80% stake in Ghana-based Sunshine Healthcare Limited.
Additionally, the parent company acquired 100% of Shahbazkers Diagnostic Centre Private Limited on May 1, 2026, for a cash consideration of INR 20.0 crore, and made further equity investments into subsidiaries such as Dr. Lal Ventures Private Limited.
01 · Business model
What does Dr. Lal PathLabs do?
Dr. Lal PathLabs Limited operates as a leading consumer healthcare brand in diagnostic services, offering an integrated nationwide network of clinical laboratories, patient service centers, and pick-up points across India.
The company provides a comprehensive test menu spanning 525 test panels, 3,130 pathology tests, and 1,173 radiology and cardiology tests, serving individual patients, hospitals, other healthcare providers, and corporate clients.
The core economic model relies on high-volume sample collection channeled through centralized reference laboratories and regional hub labs, allowing the company to capture economies of scale and maintain advanced scientific and testing capabilities.
To support long-term growth, Dr. Lal PathLabs continues to expand its footprint in Tier 3 and smaller cities, build digital and AI-driven customer interfaces, and pursue strategic international and domestic acquisitions.
02 · Historical context
What shaped the business before this quarter
Founded in 1949 by Dr. Major S. K. Lal and incorporated in 1995, the company secured early quality accreditations including NABL in 2000, ISO 9001 in 2001, and CAP international accreditation in 2002.
Between 2005 and 2015, the company built scale outside North India, established its National Reference Lab in Delhi, expanded into eastern, southern, and western regions, and completed its IPO in December 2015.
The company commissioned state-of-the-art regional reference laboratories in Kolkata (2018) and Mumbai (2023), alongside the acquisition of Suburban Diagnostics in 2021 to solidify its pan-India presence.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹797.70 Cr |
| Total income | ₹829.60 Cr |
| Profit before tax | ₹228.70 Cr |
| Profit after tax | ₹170.50 Cr |
| EPS | ₹10.13 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Q1 FY27 revenue expansion was propelled by robust operational volumes, registering 10.7% YoY sample volume growth to 25.9 million and 8.2% YoY patient volume growth to 8.2 million.
Management highlighted that revenue growth was supported by an improved test and geography mix, alongside structural tailwinds in Tier 3 and smaller cities.
Bundled preventive wellness packages under the SwasthFit program continued to contribute 27% of total revenues during the quarter.
What drove margins
Cost of materials consumed stood at INR 151.7 crore, while fees paid to collection centers and channel partners amounted to INR 115.8 crore for the quarter.
Employee benefits expense was reported at INR 132.7 crore, and other operational expenses stood at INR 150.0 crore, reflecting continued investments in staff, digital platforms, and administrative scale.
Depreciation and amortization expenses were stable at INR 44.4 crore, while finance costs stood at INR 6.3 crore.
05 · Demand, customers & order book
Where demand is coming from
The company's 'GraminFit' rural preventive healthcare outreach program, active across 7 states including UP, Bihar, MP, Rajasthan, Jharkhand, Odisha, and West Bengal, tested more than 110,000 patients in Q1 FY27.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
As evaluated by the Chief Operating Decision Maker (CODM), the company operates and allocates resources as a single diagnostic services unit under Ind AS 108, hence no separate reportable business segments are presented.
Geography and market mix
During the quarter, wholly-owned subsidiary Dr Lal Pathlabs FZCO was incorporated in Dubai, UAE, and subsequently approved the acquisition of an 80% stake in Ghana-based Sunshine Healthcare Limited to expand operations into West Africa.
Tier 3 and beyond cities continued to be a key growth engine, with Tier 3+ revenue contributions expanding steadily over prior fiscal periods.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Projects, capex and execution
The parent company made a further equity investment of INR 7.75 crore in its wholly-owned subsidiary, Dr. Lal Ventures Private Limited, during the quarter.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The parent company acquired a 100% stake in Shahbazkers Diagnostic Centre Private Limited on May 1, 2026, for a cash consideration of INR 20.0 crore, resulting in provisional goodwill of INR 14.3 crore.
Dr. Lal Ventures Private Limited approved the subscription of a 30% equity stake in Neuome Technologies Private Limited for up to INR 3.5 crore to gain access to innovative sample preservation and biobanking solutions.
The company launched four 'First in India' tests during the quarter, continued expanding its AI and next-gen technology integration, and held its first international medical conference, 'Medllumina'.
09 · Reported developments
What changed operationally
Achieved a 19.1% year-on-year increase in operating revenue for Q1 FY27, backed by double-digit sample volume growth of 10.7%.
Successfully incorporated a UAE subsidiary, initiated expansion into West Africa via Sunshine Healthcare Limited, and integrated Shahbazkers Diagnostic Centre.
10 · Items worth noticing
The line items that can distort a quick read
Other income for the quarter stood at INR 31.9 crore, contributing to total income of INR 829.6 crore.
11 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
The company maintained a robust cash and cash equivalents position of INR 1,693 crore as of June 30, 2026, providing significant strategic flexibility for inorganic growth.
Capital allocation & funding
The company maintains a high credit rating of AA+ Stable from Care Ratings Ltd., reflecting a strong balance sheet and prudent financial profile.
12 · Beyond the numbers
What changed beyond the numbers
Reported update
Grant of Stock Options
Approved the granting of 119,300 stock options to eligible employees under the Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025 at an exercise price equal to the face value of shares.
13 · Previous-quarter changes
What changed since the previous quarter
Revenue from operations rose from INR 702.7 crore in Q4 FY26 to INR 797.7 crore in Q1 FY27, while quarterly PAT improved from INR 132.2 crore to INR 170.5 crore.
14 · Key Q&A
The quarter, answered directly
What does Dr. Lal PathLabs do?
Dr. Lal PathLabs Limited operates as a leading consumer healthcare brand in diagnostic services, offering an integrated nationwide network of clinical laboratories, patient service centers, and pick-up points across India.
What is the clearest takeaway from Q1 FY27?
Dr. Lal PathLabs recorded a consolidated operational revenue of INR 797.7 crore for the quarter ended June 30, 2026, accompanied by a total income of INR 829.6 crore.
What drove revenue or demand?
Q1 FY27 revenue expansion was propelled by robust operational volumes, registering 10.7% YoY sample volume growth to 25.9 million and 8.2% YoY patient volume growth to 8.2 million.
What mattered most for margins or profitability?
Cost of materials consumed stood at INR 151.7 crore, while fees paid to collection centers and channel partners amounted to INR 115.8 crore for the quarter.
What changed operationally beyond the headline numbers?
The parent company made a further equity investment of INR 7.75 crore in its wholly-owned subsidiary, Dr. Lal Ventures Private Limited, during the quarter.
What should the next disclosure help confirm?
Monitor the completion of the first tranche investment for the 80% stake acquisition in Sunshine Healthcare Limited, Ghana, expected by August 31, 2026.
15 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
16 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Sunshine Healthcare Acquisition Closing: Monitor the completion of the first tranche investment for the 80% stake acquisition in Sunshine Healthcare Limited, Ghana, expected by August 31, 2026.
- 02
Neuome Technologies Investment Closing: Track the completion of the 30% equity subscription in Neuome Technologies Private Limited by August 31, 2026.
- 03
Rural Outreach Scaling: Observe the continued rollout and patient volume traction of the GraminFit rural preventive healthcare program across target states.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.